NVRO Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of -50.32% compared to Nevro's net margin of 4.03%. Nevro's return on equity of -42% beat Globus Medical's return on equity of 2.56%.

Nevro has a consensus price target of $6.53, signalling upside risk potential of 11.87%. On the other hand Globus Medical has an analysts' consensus of $98.08 which suggests that it could grow by 33.64%. Given that Globus Medical has higher upside potential than Nevro, analysts believe Globus Medical is more attractive than Nevro.

Nevro has a beta of 0.817, which suggesting that the stock is 18.343% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.425%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $105.5M, which are smaller than Globus Medical quarterly revenues of $657.3M. Nevro's net income of -$53.1M is lower than Globus Medical's net income of $26.5M. Notably, Nevro's price-to-earnings ratio is -- while Globus Medical's PE ratio is 97.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 4.01x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -50.32% compared to Nevro's net margin of -16.69%. Nevro's return on equity of -42% beat IRIDEX's return on equity of -157.91%.

Nevro has a consensus price target of $6.53, signalling upside risk potential of 11.87%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 101.86%. Given that IRIDEX has higher upside potential than Nevro, analysts believe IRIDEX is more attractive than Nevro.

Nevro has a beta of 0.817, which suggesting that the stock is 18.343% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $105.5M, which are larger than IRIDEX quarterly revenues of $11.6M. Nevro's net income of -$53.1M is lower than IRIDEX's net income of -$1.9M. Notably, Nevro's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 0.33x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -50.32% compared to Nevro's net margin of -2.16%. Nevro's return on equity of -42% beat Myomo's return on equity of -48.64%.

Nevro has a consensus price target of $6.53, signalling upside risk potential of 11.87%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 90.72%. Given that Myomo has higher upside potential than Nevro, analysts believe Myomo is more attractive than Nevro.

Nevro has a beta of 0.817, which suggesting that the stock is 18.343% less volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $105.5M, which are larger than Myomo quarterly revenues of $12.1M. Nevro's net income of -$53.1M is lower than Myomo's net income of -$260.1K. Notably, Nevro's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 5.63x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -50.32% compared to Nevro's net margin of -118.53%. Nevro's return on equity of -42% beat Stereotaxis's return on equity of -139.2%.

Nevro has a consensus price target of $6.53, signalling upside risk potential of 11.87%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 163.16%. Given that Stereotaxis has higher upside potential than Nevro, analysts believe Stereotaxis is more attractive than Nevro.

Nevro has a beta of 0.817, which suggesting that the stock is 18.343% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $105.5M, which are larger than Stereotaxis quarterly revenues of $6.3M. Nevro's net income of -$53.1M is lower than Stereotaxis's net income of -$7.5M. Notably, Nevro's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 5.41x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.